These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25138390)

  • 21. Pill counts and pill rental: unintended entrepreneurial opportunities.
    Viscomi CM; Covington M; Christenson C
    Clin J Pain; 2013 Jul; 29(7):623-4. PubMed ID: 23328335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlates of Prescription Opioid Legitimacy Judgments Among Community Pharmacists.
    Hagemeier NE; Alamian A; Murawski MM; Flippin H; Hagy EJ; Pack RP
    Subst Use Misuse; 2016 May; 51(6):692-9. PubMed ID: 27070040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey.
    Alvin M; Picco L; Wood P; Mnatzaganian G; Nielsen S
    Int J Clin Pharm; 2021 Apr; 43(2):411-419. PubMed ID: 32951182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk assessment and counseling behaviors of healthcare professionals managing patients with chronic pain: a national multifaceted assessment of physicians, pharmacists, and their patients.
    Salinas GD; Susalka D; Burton BS; Roepke N; Evanyo K; Biondi D; Nicholson S
    J Opioid Manag; 2012; 8(5):273-84. PubMed ID: 23247904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Community pharmacists' prescription intervention practices--exploring variations in practice in Norwegian pharmacies.
    Mandt I; Horn AM; Ekedahl A; Granas AG
    Res Social Adm Pharm; 2010 Mar; 6(1):6-17. PubMed ID: 20188324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacist Views Regarding the Prescription Opioid Epidemic.
    Rao D; Giannetti V; Kamal KM; Covvey JR; Tomko JR
    Subst Use Misuse; 2021; 56(14):2096-2105. PubMed ID: 34429024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prescription changes in pharmacies].
    Mandt I; Horn AM; Granås AG
    Tidsskr Nor Laegeforen; 2006 Jun; 126(13):1754-5. PubMed ID: 16794671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urine drug testing in chronic pain.
    Christo PJ; Manchikanti L; Ruan X; Bottros M; Hansen H; Solanki DR; Jordan AE; Colson J
    Pain Physician; 2011; 14(2):123-43. PubMed ID: 21412368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacists' knowledge of and attitudes toward opioid pain medications in relation to federal and state policies.
    Joranson DE; Gilson AM
    J Am Pharm Assoc (Wash); 2001; 41(2):213-20. PubMed ID: 11297334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the role of Urine Drug Testing (UDT) in the management of chronic non-cancer pain with opioids?
    Schonwald G
    Pain Med; 2012 Jul; 13(7):853-6. PubMed ID: 22804903
    [No Abstract]   [Full Text] [Related]  

  • 31. Collaborative working relationships between pharmacists and physicians: an exploratory study.
    Brock KA; Doucette WR
    J Am Pharm Assoc (2003); 2004; 44(3):358-65. PubMed ID: 15191246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What's trust got to do with it? Revisiting opioid contracts.
    Buchman DZ; Ho A
    J Med Ethics; 2014 Oct; 40(10):673-7. PubMed ID: 24014642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment. Prescribers' practices].
    Feroni I; Aubisson S; Bouhnik AD; Paraponaris A; Masut A; Coudert C; Obadia Y
    Presse Med; 2005 Oct; 34(17):1213-9. PubMed ID: 16230961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances.
    Fendrich M; Bryan JK; Hooyer K
    Subst Use Misuse; 2018 Jul; 53(8):1324-1330. PubMed ID: 29297725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.
    Salwan A; Hagemeier NE; Tudiver F; Dowling-McClay K; Foster KN; Arnold J; Alamian A; Pack RP
    J Am Pharm Assoc (2003); 2020; 60(6):e173-e178. PubMed ID: 32669219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New policing role for pharmacists undermines partnership with prescribers.
    Webster LR
    Pain Med; 2013 Nov; 14(11):1619-20. PubMed ID: 24238350
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of a clinical pharmacist-led guidance team on cancer pain therapy in China: a prospective multicenter cohort study.
    Chen J; Lu XY; Wang WJ; Shen B; Ye Y; Jiang H; Wang QS; Cheng B
    J Pain Symptom Manage; 2014 Oct; 48(4):500-9. PubMed ID: 24726204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy.
    Roberts AW; Farley JF; Holmes GM; Oramasionwu CU; Ringwalt C; Sleath B; Skinner AC
    Health Aff (Millwood); 2016 Oct; 35(10):1884-1892. PubMed ID: 27702963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician beliefs and attitudes toward collaboration with community pharmacists.
    Kucukarslan S; Lai S; Dong Y; Al-Bassam N; Kim K
    Res Social Adm Pharm; 2011 Sep; 7(3):224-32. PubMed ID: 21272527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond the paper trail: using technology to reduce escalating harms from opioid prescribing in Australia.
    Nicholas R; Roche A; Dobbin M; Lee N
    Aust N Z J Public Health; 2013 Apr; 37(2):139-47. PubMed ID: 23551472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.